Home/Filings/4/0001104659-23-128788
4//SEC Filing

Jin David 4

Accession 0001104659-23-128788

CIK 0001429260other

Filed

Dec 21, 7:00 PM ET

Accepted

Dec 22, 4:05 PM ET

Size

5.9 KB

Accession

0001104659-23-128788

Insider Transaction Report

Form 4
Period: 2023-12-20
Jin David
Chief Financial Officer
Transactions
  • Award

    COMMON STOCK, PAR VALUE $0.001

    2023-12-20+140,000235,916 total
Footnotes (3)
  • [F1]Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split.
  • [F2]Represents an award of 140,000 restricted stock units which will vest in 16 equal quarterly installments after the grant date, December 20, 2023. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Corporate Transaction (as defined in the Fortress Biotech, Inc. 2013 Stock Incentive Plan); the amount will be distributed in the form of the Issuer's common stock.
  • [F3]Total holdings include 230,000 shares underlying deferred restricted stock units.

Issuer

Fortress Biotech, Inc.

CIK 0001429260

Entity typeother

Related Parties

1
  • filerCIK 0001930732

Filing Metadata

Form type
4
Filed
Dec 21, 7:00 PM ET
Accepted
Dec 22, 4:05 PM ET
Size
5.9 KB